On June 23, Zai Lab rose 5.46% in regular trading, trading at 14.67 HKD/share, with turnover of 33.80 million HKD.

On the news front, the biotechnology sector saw broad-based strength, with AKESO up 6.51%, Remegen up 5.47%, Innovent Bio up 4.78%, and BeiGene up 4.22%, creating a significant sector linkage effect. The rally carries characteristics of an oversold rebound, as Zai Lab dropped over 5% the previous session after partner Novocure announced that its tumor treating fields therapy TTFields failed to meet the overall survival primary endpoint in the Phase III TRIDENT trial for newly diagnosed glioblastoma, with mOS of 17.7 months versus 17.5 months (HR=0.953, p=0.519). Zai Lab holds Greater China rights to TTFields, marketed domestically under the OPTUNE brand, which contributed approximately 48 million USD in sales in 2025.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)